Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
enVVeno MedicalNVNO -0.91%26 3-Year RORE % is -20.53 as of Mar. 2026. GuruFocus rates NVNO with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 777 Medical Devices & Instruments companies, enVVeno Medical ranks worse than 66.54% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
enVVeno Medical's 3-Year RORE % for the quarter that ended in Mar. 2026 was -20.53%.
The industry rank for enVVeno Medical's 3-Year RORE % or its related term are showing as below:
NVNO's 3-Year RORE % is ranked worse than 66.54% of 777
companies
in the Medical Devices & Instruments industry
Industry Median: -4.03
vs NVNO: -20.53
enVVeno Medical (NAS:NVNO) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
enVVeno Medical 3-Year RORE % Related Terms
enVVeno Medical 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for enVVeno Medical's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NVNO vs STME, TRIB, AIDX: 3-Year RORE % Comparison
For the Medical Devices subindustry, enVVeno Medical's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
enVVeno Medical 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, enVVeno Medical's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where enVVeno Medical's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
enVVeno Medical (NVNO) has a 3-Year RORE % of -20.53 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on enVVeno Medical and its competitors. According to the industry distribution chart, enVVeno Medical ranks #517 out of 777 companies in the Medical Devices & Instruments industry, placing it in the top 66.5%.
Is enVVeno Medical's 3-Year RORE % too high?
enVVeno Medical's current 3-Year RORE % is -20.53. Based on the distribution chart, enVVeno Medical ranks #517 out of 777 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, enVVeno Medical has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does enVVeno Medical's 3-Year RORE % compare to STME and TRIB?
According to the Medical Devices & Instruments industry distribution chart, enVVeno Medical ranks #517 out of 777 companies for 3-Year RORE %. This places enVVeno Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on enVVeno Medical and its competitors. enVVeno Medical's current 3-Year RORE % is -20.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enVVeno Medical stock overvalued right now?
enVVeno Medical (NVNO) has a current 3-Year RORE % of -20.53. The current 3-Year RORE % is -20.53. enVVeno Medical's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For enVVeno Medical (NVNO), the current 3-Year RORE % is -20.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
26GF Score
Get the complete analysis for NVNO
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVNO has been successfully added to your 
